Annovis Soars On Parkinson’s Failure

Buntanetap misses the primary endpoint in another Phase III trial but investors are swayed by exploratory analyses.

Loser concept. Hand drawn failure in business. Unfortunate attempt to hit the target isolated vector illustration.

Following the recent miss in its Alzheimer’s disease trial of buntanetap, Annovis Bio, Inc. really needed a hit in its pivotal trial of the same drug in Parkinson’s. On 2 July, it said it had seen positive data and its shares climbed 76% to close at $9.28 on the New York Stock Exchange.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Can European Biotech Survive And Thrive In Era Of Instability?

30 Apr 2025

• By Andrew McConaghie

Europe's biopharma sector could suffer if the Trump administration incentivizes US investment but VC leaders believe the region can still thrive and potentially capitalize on instability elsewhere.